Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives

Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives

The hemodynamic stabilization of neurocritical care patients demands a nuanced understanding of receptor pharmacology, cardiovascular mechanics, and cerebrovascular physiology. Vasoactive agents are deployed to augment cerebral perfusion pressure ($CPP$), manage neurogenic and distributive shock, support neurogenic myocardial dysfunction, and strictly control arterial blood pressure in acute stroke and intracranial hemorrhage. Selecting the wrong agent can precipitate myocardial ischemia, secondary brain edema, intracranial hypertension, or fatal cerebral hypoperfusion.

Receptor Pharmacology in Hemodynamic Regulation

Vasoactive infusions exert their therapeutic and adverse effects by engaging specific cell-surface receptors across vascular smooth muscle, cardiac myocytes, and specialized conduction tissues:

---

Vasopressors and Inotropes in the Neuro-ICU

Norepinephrine ($\alpha_1 > \beta_1$)

• Mechanism: Potent $\alpha_1$ agonist with modest $\beta_1$ inotropic activity and minimal $\beta_2$ effect.
• Hemodynamic Profile: Increases systemic vascular resistance ($SVR$), arterial blood pressure, and effective circulating volume (via venoconstriction of capacitance vessels). Stroke volume is generally preserved or slightly increased due to enhanced venous return and direct inotropy, counterbalancing increased afterload.
• Clinical Role: First-line vasopressor for septic shock, neurogenic shock, traumatic brain injury, and induced hypertension for delayed cerebral ischemia ($DCI$) in subarachnoid hemorrhage.
• Dosing: $0.01\text{--}3.0\ \mu\text{g/kg/min}$ (or $1\text{--}30\ \mu\text{g/min}$), titrated to target $MAP$ or $CPP$.

Phenylephrine (Pure $\alpha_1$)

• Mechanism: Pure synthetic $\alpha_1$ agonist completely devoid of direct $\beta$-adrenergic activity.
• Hemodynamic Profile: Induces rapid, intense arteriolar vasoconstriction, sharply increasing $SVR$ and $MAP$.
• Clinical Pitfall & Role: The abrupt increase in afterload coupled with the absence of $\beta_1$ chronotropy triggers a prominent baroreceptor-mediated reflex bradycardia. In patients with underlying left ventricular dysfunction, phenylephrine can cause a marked reduction in stroke volume and cardiac index.
• Indications: Indicated when norepinephrine is limited by severe tachyarrhythmias, or in patients with dynamic left ventricular outflow tract ($LVOT$) obstruction (Takotsubo cardiomyopathy) where inotropy must be avoided.

Vasopressin ($V_1$ Agonist)

• Mechanism: Exogenous arginine vasopressin activates vascular $V_1$ receptors, stimulating phospholipase C and mobilizing intracellular calcium.
• Hemodynamic Profile: Causes intense vasoconstriction without direct adrenergic stimulation. Unlike catecholamines, vasopressin remains biologically active in the presence of severe lactic acidosis and hypoxia.
• Clinical Role: Second-line catecholamine-sparing agent in septic and neurogenic shock. Particularly valuable in neuro-ICU patients who develop central diabetes insipidus ($DI$) following pituitary surgery or severe traumatic brain injury, simultaneously resolving polyuria and supporting blood pressure.
• Dosing & Caution: Administered as a fixed, non-titrated continuous infusion at $0.03\text{--}0.04\text{ units/min}$. Titrating above $0.04\text{ units/min}$ increases the risk of severe splanchnic hypoperfusion, coronary vasospasm, and digital gangrene.

Epinephrine ($\beta_1, \beta_2$ at low doses; $\alpha_1$ at higher doses)

• Mechanism: Non-selective adrenergic agonist. At low doses ($< 0.05\ \mu\text{g/kg/min}$), $\beta_1$ and $\beta_2$ effects predominate, increasing cardiac contractility, heart rate, and cardiac output while mildly reducing $SVR$. At higher doses ($> 0.1\ \mu\text{g/kg/min}$), $\alpha_1$ effects predominate, producing intense vasoconstriction.
• Clinical Role: Second-line agent for refractory cardiogenic or distributive shock and anaphylaxis.
• Metabolic Pitfall: Epinephrine stimulates skeletal muscle $\beta_2$ receptors, activating membrane-bound $\text{Na}^+/\text{K}^+$-ATPase pumps and accelerating cellular glycolysis. This produces excess pyruvate that exceeds pyruvate dehydrogenase capacity, converting into lactate (Type B aerobic hyperlactatemia). This pharmacologic hyperlactatemia must not be misinterpreted as worsening tissue hypoperfusion.

Inodilators: Dobutamine and Milrinone

Inodilators are deployed in the neuro-ICU primarily to manage neurogenic stunned myocardium ($NSM$), Takotsubo cardiomyopathy with cardiogenic shock, and acute left ventricular decompensation.

---

Intravenous Antihypertensive Agents

Rapid, titratable blood pressure reduction is essential in acute ischemic stroke ($AIS$), spontaneous intracerebral hemorrhage ($ICH$), and pre-securing aneurysmal subarachnoid hemorrhage ($aSAH$).

Nicardipine

• Mechanism: Dihydropyridine L-type calcium channel blocker with high selectivity for vascular smooth muscle over cardiac tissue.
• Hemodynamic Profile: Rapid systemic arteriolar vasodilation with minimal to no negative inotropic or dromotropic effect. It produces a predictable, smooth dose-dependent reduction in blood pressure without sudden precipitously low troughs.
• Cerebrovascular Effects: Dilates cerebral vessels without increasing intracranial pressure at therapeutic doses, making it the premier continuous infusion across neurovascular emergencies.
• Titration: Initiate at $5\text{ mg/h}$ IV; titrate by $2.5\text{ mg/h}$ every 5–15 minutes to target (maximum $15\text{ mg/h}$). Once target is achieved, reduce infusion rate to $3\text{ mg/h}$ for maintenance.

Clevidipine

• Mechanism: Third-generation, ultra-short-acting dihydropyridine calcium channel blocker formulated in a $20\%$ lipid emulsion.
• Pharmacokinetics: Metabolized by non-specific blood and tissue esterases. It exhibits an ultra-rapid onset ($2\text{--}4\text{ minutes}$) and offset ($5\text{--}15\text{ minutes}$), independent of hepatic or renal function.
• Advantages in Neuro-ICU: Unparalleled minute-by-minute titration precision. In acute stroke patients undergoing thrombolysis or EVT, clevidipine allows rapid attainment of the $< 180/105\text{ mmHg}$ target without risk of prolonged "overshoot" hypotension that could infarct the ischemic penumbra.
• Dosing & Safety: Start at $1\text{--}2\text{ mg/h}$; double dose every 90 seconds until near target, then titrate in smaller increments up to $32\text{ mg/h}$. Because it is formulated in a lipid emulsion ($2\text{ kcal/mL}$), strict aseptic handling, vial changes every 12 hours, and monitoring for hypertriglyceridemia are required. Contraindicated in severe egg or soy allergy.

Labetalol

• Mechanism: Combined selective $\alpha_1$ and non-selective $\beta_1/\beta_2$ adrenergic antagonist. When administered intravenously, the ratio of $\alpha$-to-$\beta$ blockade is approximately $1:7$.
• Hemodynamic Profile: Decreases systemic vascular resistance via $\alpha_1$ antagonism while blunting reflex tachycardia and decreasing myocardial contractility via $\beta_1$ antagonism.
• Clinical Role: Ideal for patients presenting with simultaneous acute hypertension and sinus tachycardia. Often administered as intermittent boluses ($10\text{--}20\text{ mg}$ IV over 2 minutes, repeating or doubling every 10 minutes up to $300\text{ mg}$ total) or as a continuous infusion ($1\text{--}8\text{ mg/min}$).
• Contraindications: Second- or third-degree heart block, severe sinus bradycardia ($\text{HR} < 60\text{ bpm}$), acute decompensated systolic heart failure, and active severe reactive airway disease (bronchospasm).

---

Hazardous Vasodilators in Neurocritical Care: Hydralazine & Nitroprusside